ライフサイエンスコーパス: conjugate vaccine

1 derived from mice vaccinated with a fentanyl conjugate vaccine.

2 either Vi-TCV or a meningococcal serogroup A conjugate vaccine.

3 ), and documented the impact of pneumococcal conjugate vaccine.

4 011, before the introduction of pneumococcal conjugate vaccine.

5 ntinue to inform programmatic use of typhoid conjugate vaccine.

6 he now-licensed, highly effective MenAfriVac conjugate vaccine.

7 ered by the licensed 13-valent S. pneumoniae conjugate vaccine.

8 e nuances of typhoid disease and the typhoid conjugate vaccine.

9 t are included in the 10-valent pneumococcal conjugate vaccine.

10 nd local levels to introduce the new typhoid conjugate vaccine.

11 00, even before nationwide implementation of conjugate vaccines.

12 CPS-based polysaccharide and polysaccharide-conjugate vaccines.

13 decisions related to the rollout of typhoid conjugate vaccines.

14 th age but not by serotypes in the different conjugate vaccines.

15 n prevention of TH2 responses by flagellin A conjugate vaccines.

16 broad-ranging Salmonella lipopolysaccharide conjugate vaccines.

17 sh the design principles for improved glycan conjugate vaccines.

18 lude vaccine strategies with the new typhoid conjugate vaccines.

19 sess the key characteristics of conventional conjugate vaccines.

20 rials and help guide the design of effective conjugate vaccines.

21 tion and control measures, including typhoid conjugate vaccines.

22 ntrol measures, including the use of typhoid conjugate vaccines.

23 strategies, namely, introduction of typhoid conjugate vaccines.

24 Pneumococcal conjugate vaccine 10 (PCV10) and pneumococcal conjugate

25 onjugate vaccine 10 (PCV10) and pneumococcal conjugate vaccine 13 (PCV13), are used in childhood immu

26 effectiveness of the 13-valent pneumococcal conjugate vaccine (2012-2016) to prevent all-cause pneum

27 Carbohydrate conjugate vaccines achieve this by coupling bacterial po

28 d to support country decisions about typhoid conjugate vaccine adoption.

29 le in the clinically relevant polysaccharide conjugate vaccine against Streptococcus pneumoniae (pneu

30 Widespread vaccination with conjugate vaccines against Haemophilus influenzae and St

31 ive strategies, including the polysaccharide conjugate vaccines, aim to eliminate asymptomatic carria

32 and to consider the effects of pneumococcal conjugate vaccine and rotavirus vaccine in the estimatio

33 le-up and widespread use of the pneumococcal conjugate vaccine and sustained use of the Hib vaccine c

34 entered on supporting development of typhoid conjugate vaccines and expanding disease surveillance ef

35 of households, we estimate that pneumococcal conjugate vaccines and live attenuated rotavirus vaccine

36 tolerability, and immunogenicity of typhoid conjugate vaccine, and early efficacy results are promis

37 ed with pneumococcal capsular polysaccharide conjugate vaccine, and then sequentially coinfected 5 we

38 Conjugate vaccines are an effective way to create a long

39 Affordable multivalent meningococcal conjugate vaccines are being developed to prevent these

40 Pneumococcal conjugate vaccines are important tools in the approach t

41 ine production and capsular oligosaccharides conjugate vaccines are proven effective against infectio

42 olysaccharide-protein conjugate vaccines (Vi-conjugate vaccines) are immunogenic and can be used from

43 berations on strategies to introduce typhoid conjugate vaccine as a preventive tool against enteric f

44 Conjugate vaccine-associated indirect protection for adu

45 er at 11 months and a 10-valent pneumococcal conjugate vaccine at 2, 4, and 11 months after birth.

46 + 0" infant schedule (13-valent pneumococcal conjugate vaccine at 2, 4, and 6 months) to a "2 + 1" sc

47 or licensure of a GBS polysaccharide-protein conjugate vaccine based on immunogenicity evaluation ben

48 Until an affordable multivalent conjugate vaccine becomes available, the need for timely

49 lf-life extension, antibody-drug conjugates, conjugate vaccines, bispecific antibodies and cell thera

50 gy it is expected that multivalent O antigen conjugate vaccines can be produced at industrial scale.

51 ntions, including mass vaccination with a Vi-conjugate vaccine coadministered with measles vaccine ar

52 A conjugate vaccine consisting of recombinant Fel d 1 and

53 Chemical synthesis of conjugate vaccines, consisting of a polysaccharide linke

54 A conjugate vaccine containing Haemophilus influenzae type

55 effective low-cost multivalent meningococcal conjugate vaccine could help further control meningococc

56 Early immunization with typhoid conjugate vaccines could avert substantial morbidity, bu

57 o occur; effective multivalent meningococcal conjugate vaccines could improve meningococcal disease p

58 The ability of GBS polysaccharide-protein conjugate vaccines currently under development to induce

59 Haemophilus influenzae type b (Hib) conjugate vaccine, delivered as a three-dose series with

60 This Vi-based conjugate vaccine demonstrated robust immunogenicity aft

61 he intact virus represents a step forward in conjugate vaccine design because it provides multiple an

62 ction of MenAfriVac, a meningococcal group A conjugate vaccine developed for the African meningitis b

63 n 2-30 months old in a 7-valent pneumococcal conjugate vaccine dosing trial.

64 ted a remarkable ability to adapt during the conjugate vaccine era.

65 B streptococcus (GBS) polysaccharide-protein conjugate vaccine for protecting infants against invasiv

66 World Health Organization recommends typhoid conjugate vaccines for country-specific introduction, bu

67 commendation for the introduction of typhoid conjugate vaccines for infants and children aged >6 mont

68 Organization (WHO) to develop meningococcal conjugate vaccines for sub-Saharan Africa.

69 Capsular polysaccharide conjugate vaccine GBS6 was designed using surveillance d

70 Pneumococcal conjugate vaccines have been successful, but their use h

71 Capsular polysaccharide conjugate vaccines have been tested in phase I/II clinic

72 Conjugate vaccines have not completely overcome this cha

73 roup C Neisseria meningitidis tetanus toxoid conjugate vaccine (Hib-MenC-TT), administered in the lef

74 e (PsACWY); or Haemophilus influenzae type b conjugate vaccine (Hib-TT).

75 ) linked to FP8 (FP8-rTTHC) as a suitable FP-conjugate vaccine immunogen.

76 The study was conducted before pneumococcal conjugate vaccine implementation in Israel.

77 he introduction of meningococcal serogroup A conjugate vaccine in 2010.

78 e introduction of the 13-valent pneumococcal conjugate vaccine in 2011.

79 ed persons with a quadrivalent meningococcal conjugate vaccine in accordance with Advisory Committee

80 To determine the efficacy of a new typhoid conjugate vaccine in an endemic setting in sub-Saharan A

81 ng the efficacy of a newly developed typhoid conjugate vaccine in an urban setting in Nepal.

82 endations for widespread use of pneumococcal conjugate vaccine in low-income and middle-income countr

83 control interventions including the typhoid conjugate vaccine in the poor communities that have hist

84 of goods" to develop a group A - containing conjugate vaccine in the United States would be in the r

85 d by WHO for the programmatic use of typhoid conjugate vaccines in endemic countries.

86 provide some support for the introduction of conjugate vaccines in Nepal, including outside urban are

87 rranted as the decision to introduce protein conjugated vaccine in India is made.

88 e examine the effect of a glycolipid-peptide conjugate vaccine incorporating an NKT cell-activating g

89 cocci, and investigated whether pneumococcal conjugate vaccine-induced serotype 6A and 6B antibodies

90 was common, highlighting a role for typhoid conjugate vaccine into routine infant vaccine schedules.

91 aims to support the introduction of typhoid conjugate vaccines into Gavi-eligible countries in an ef

92 stributions were observed after pneumococcal conjugate vaccine introduction at regional levels and am

93 in pneumococcal meningitis post-pneumococcal conjugate vaccine introduction in Senegal.

94 ed from Israeli children before pneumococcal conjugate vaccine introduction.

95 cal proof of concept of a 4-valent O antigen conjugate vaccine is ongoing.

96 A novel meningococcal serogroup A conjugate vaccine (MACV [MenAfriVac]) was developed as p

97 After successful meningococcal serogroup A conjugate vaccine (MACV) campaigns since 2010, Burkina F

98 -Saharan Africa, a meningococcal serogroup A conjugate vaccine (MACV) has been progressively rolled o

99 rollout of a novel meningococcal serogroup A conjugate vaccine (MACV) in the belt, the World Health O

100 In 2010-2017, meningococcal serogroup A conjugate vaccine (MACV) was introduced in 21 African me

101 Meningococcal serogroup A conjugate vaccine (MACV) was introduced in Chad during 2

102 logy and impact of meningococcal serogroup A conjugate vaccine (MACV).

103 ion campaigns with meningococcal serogroup A conjugate vaccine (MACV).

104 tries introduced a meningococcal serogroup A conjugate vaccine (MACV).

105 e availability of an affordable, multivalent conjugate vaccine may be important in future epidemic re

106 Glycolipid-peptide conjugate vaccines may prove useful for the prevention o

107 accine (YFV) at 9 months and meningococcal A conjugate vaccine (MCV-A) at 15 months, in addition to m

108 er a TCV or a capsular group A meningococcal conjugate vaccine (MenA) as a control.

109 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control.

110 n meningitis belt with group A meningococcal conjugate vaccine, MenAfriVac (PsA-TT), disease due to g

111 n and rollout of a meningococcal serogroup A conjugate vaccine, MenAfriVac, in the African meningitis

112 lipid A analogue, in the generation of novel conjugate-vaccine modalities.

113 ization prequalification should make typhoid conjugate vaccine more accessible and affordable in low-

114 yse the effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in En

115 control (meningococcal group A, C, W, and Y conjugate vaccine or saline).

116 Four main processes determine pneumococcal conjugate vaccine (PCV) antibiotic-nonsusceptible Strept

117 , among children immunized with pneumococcal conjugate vaccine (PCV) both before and after IPD, the p

118 Vaccinating children with pneumococcal conjugate vaccine (PCV) disrupts transmission, reducing

119 r transplant, giving 3 doses of pneumococcal conjugate vaccine (PCV) followed by either a dose of 23-

120 ansplant, giving three doses of pneumococcal conjugate vaccine (PCV) followed by either a dose of pne

121 The widespread use of pneumococcal conjugate vaccine (PCV) has brought about a dramatic dec

122 Pneumococcal conjugate vaccine (PCV) implementation has led to a shar

123 ave not been reported following pneumococcal conjugate vaccine (PCV) implementation.

124 included in the pneumococcal polysaccharide conjugate vaccine (PCV) in 2000 before it was expanded i

125 untries to study the benefit of pneumococcal conjugate vaccine (PCV) in protecting against invasive p

126 Data on pneumococcal conjugate vaccine (PCV) indirect effects in low-income c

127 le settings.Fifteen years after pneumococcal conjugate vaccine (PCV) introduction and 5 years post-PC

128 Following pneumococcal conjugate vaccine (PCV) introduction in 2011, annual sus

129 eumococcal meningitis following pneumococcal conjugate vaccine (PCV) introduction.

130 eumococci from before and after pneumococcal conjugate vaccine (PCV) introductions and were from chil

131 ined following 7- and 13-valent pneumococcal conjugate vaccine (PCV) introductions worldwide.

132 Pneumococcal conjugate vaccine (PCV) is now recommended for use in ad

133 Universal pneumococcal conjugate vaccine (PCV) programs began in Indigenous Aus

134 Universal pneumococcal conjugate vaccine (PCV) programs began in Indigenous Aus

135 Reduced-dose pneumococcal conjugate vaccine (PCV) schedules are under consideratio

136 Reduced-dose pneumococcal conjugate vaccine (PCV) schedules are under consideratio

137 was a significant reduction of pneumococcal conjugate vaccine (PCV) serotypes, from 44.4% in 2011 to

138 to consider whether to continue pneumococcal conjugate vaccine (PCV) use at full cost or to discontin

139 Pneumococcal conjugate vaccine (PCV) was introduced into Alberta, Can

140 upport decisions on introducing pneumococcal conjugate vaccine (PCV).

141 New Zealand introduced pneumococcal conjugate vaccine (PCV)7 in June 2008, PCV10 in 2011, an

142 Pneumococcal conjugate vaccines (PCV) are highly protective against i

143 full extent to which childhood pneumococcal conjugate vaccines (PCV) can indirectly reduce illness i

144 studies assessing the impact of pneumococcal conjugate vaccines (PCV) on burden of pneumococcal sepsi

145 Kenya introduced 10-valent pneumococcal conjugate vaccine (PCV10) among children <1 year in 2011

146 Zambia introduced a 10-valent pneumococcal conjugate vaccine (PCV10) in July 2013 using a 3-dose pr

147 t of introduction of ten-valent pneumococcal conjugate vaccine (PCV10) on pneumonia mortality in chil

148 immunisation with a ten-valent pneumococcal conjugate vaccine (PCV10) using three primary doses and

149 on-typeable Haemophilus influenzae protein D conjugate vaccine (PCV10) was introduced in Kenya in Jan

150 The 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in Madagascar i

151 lese infants receive ten-valent pneumococcal conjugate vaccine (PCV10) with a 1 month interval betwee

152 Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 we

153 he immune response to 13-valent pneumococcal conjugate vaccine (PCV13) administration 4 to 5 years la

154 , the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) against first episodes of vacc

155 Five sites use 13-valent pneumococcal conjugate vaccine (PCV13) alone and four use the ten-val

156 those included in the 13-valent pneumococcal conjugate vaccine (PCV13) and the remaining non-PCV13 se

157 ived DTaP-IPV-Hib and 13-valent pneumococcal conjugate vaccine (PCV13) concurrently, followed by 23-v

158 the immunogenicity of 13-valent pneumococcal conjugate vaccine (PCV13) during and after chemotherapy.

159 vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumoco

160 e primary dose of the 13-valent pneumococcal conjugate vaccine (PCV13) from the existing 2+1 schedule

161 Zimbabwe introduced 13-valent pneumococcal conjugate vaccine (PCV13) in 2012 using a 3-dose infant

162 mbodia introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in January 2015 using a 3 + 0

163 Senegal introduced a 13-valent pneumococcal conjugate vaccine (PCV13) in October 2013, given at 6, 1

164 te vaccine (PCV7) and 13-valent pneumococcal conjugate vaccine (PCV13) in the childhood vaccination p

165 rkina Faso introduced 13-valent pneumococcal conjugate vaccine (PCV13) into the routine childhood imm

166 The impact of 13-valent pneumococcal conjugate vaccine (PCV13) introduction on the occurrence

167 The 13-valent pneumococcal conjugate vaccine (PCV13) is the only licensed PCV with

168 The impact of 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal meningitis (PM

169 The 13-valent pneumococcal conjugate vaccine (PCV13) protects against key serotypes

170 In 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7 in many jurisdic

171 In 2010, the 13-valent pneumococcal conjugate vaccine (PCV13) replaced PCV7.

172 relation to PPV23/non-13-valent pneumococcal conjugate vaccine (PCV13) serotype pneumonia (n = 417 ca

173 es, one or both isolates were a pneumococcal conjugate vaccine (PCV13) serotype.

174 The 13-valent pneumococcal conjugate vaccine (PCV13) was designed to include diseas

175 lated infections, the 13-valent pneumococcal conjugate vaccine (PCV13) was initially introduced in th

176 In March 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) was introduced to the routine

177 P = 0.004), after the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced.

178 In 2010, 13-valent pneumococcal conjugate vaccine (PCV13) was licensed and recommended i

179 or 13 serotypes included in the pneumococcal conjugate vaccine (PCV13) was recently reported as a use

180 013, a single dose of 13-valent pneumococcal conjugate vaccine (PCV13) was recommended for immunocomp

181 (Hib) vaccine and the 13-valent pneumococcal conjugate vaccine (PCV13) were introduced in 2008 and 20

182 fety surveillance for 13-valent pneumococcal conjugate vaccine (PCV13), comparing the risk of Kawasak

183 e introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), ST diversity increased in chi

184 c introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), there is residual carriage an

185 14 weeks) and 13-valent pneumococcal CRM197-conjugate vaccine (PCV13; age 6/14 weeks and 9 months).

186 (vaccinated with the 13-valent pneumococcal conjugate vaccine [PCV13] as part of the Expanded Progra

187 eased since the introduction of pneumococcal conjugate vaccine (PCV7 and PCV13).

188 ng the introduction of 7-valent pneumococcal conjugate vaccine (PCV7) and 13-valent pneumococcal conj

189 a introduced universal 7-valent pneumococcal conjugate vaccine (PCV7) from 2005, replaced by 13-valen

190 carriage compared with 7-valent pneumococcal conjugate vaccine (PCV7) immunized children, N = 567, en

191 Introduction of the heptavalent pneumococcal conjugate vaccine (PCV7) in 2000 reduced macrolide-resis

192 ction of the pediatric 7-valent pneumococcal conjugate vaccine (PCV7) in 2000.

193 in the UK were first offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at 2 and 4 month

194 the introduction of a 7-valent pneumococcal conjugate vaccine (PCV7) in childhood immunization progr

195 lowing introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in the United States, epidemiol

196 the impact of the seven-valent pneumococcal conjugate vaccine (PCV7) on pneumococcal carriage and th

197 who were enrolled in a 7-valent pneumococcal conjugate vaccine (PCV7) trial.

198 aHRs) for OM comparing 7-valent pneumococcal conjugate vaccine (PCV7)-era (2006-2010) and PCV13-era (

199 , many can be prevented by PCVs.Pneumococcal conjugate vaccine (PCV7/PCV13) implementation resulted i

200 0, 1, 2, or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) in infancy followed by

201 duction of the 7- and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) altere

202 The 7-valent and 13-valent pneumococcal conjugate vaccines (PCV7 and PCV13, respectively) are hi

203 ns, the protection conferred by pneumococcal conjugate vaccines (PCVs) against pediatric pneumonia at

204 Pneumococcal conjugate vaccines (PCVs) are being used worldwide.

205 Pneumococcal conjugate vaccines (PCVs) are highly effective in preven

206 Pneumococcal conjugate vaccines (PCVs) are used in many low-income co

207 h, even though highly effective pneumococcal conjugate vaccines (PCVs) are used in national immunizat

208 component of current protein-polysaccharide conjugate vaccines (PCVs) generally induces immunity spe

209 Introduction of pneumococcal conjugate vaccines (PCVs) has shown a marked reduction i

210 Introduction of pneumococcal conjugate vaccines (PCVs) has substantially reduced dise

211 OM) burden following rollout of pneumococcal conjugate vaccines (PCVs) have exceeded predictions of v

212 Pneumococcal conjugate vaccines (PCVs) have had a well-documented imp

213 Pneumococcal conjugate vaccines (PCVs) have reduced pneumococcal dise

214 Pneumococcal conjugate vaccines (PCVs) have significantly decreased p

215 Pneumococcal conjugate vaccines (PCVs) have substantially reduced the

216 The use of pneumococcal conjugate vaccines (PCVs) in children has a strong indir

217 ciated with the introduction of pneumococcal conjugate vaccines (PCVs) in five countries in the Ameri

218 s available about the effect of pneumococcal conjugate vaccines (PCVs) in low-income countries.

219 The continuing impact of pneumococcal conjugate vaccines (PCVs) in regions with high pneumococ

220 Use of pneumococcal conjugate vaccines (PCVs) in resource-poor countries has

221 There are concerns that pneumococcal conjugate vaccines (PCVs) in sub-Saharan Africa sub-opti

222 The introduction of pneumococcal conjugate vaccines (PCVs) into childhood vaccination pro

223 s of childhood vaccination with pneumococcal conjugate vaccines (PCVs) is unknown.

224 anding the real-world effect of pneumococcal conjugate vaccines (PCVs) on pneumonia mortality is cruc

225 Pneumococcal conjugate vaccines (PCVs) target only a few serotypes th

226 relation to the introduction of pneumococcal conjugate vaccines (PCVs), before (2005- 2009), during (

227 een the two currently available pneumococcal conjugate vaccines (PCVs), ten-valent PCV (PCV10) and 13

228 portant human pathogen, and the pneumococcal conjugate vaccines (PCVs), which target only a fraction

229 antly since the introduction of pneumococcal conjugate vaccines (PCVs).

230 rends after the introduction of pneumococcal conjugate vaccines (PCVs).

231 Pneumococcal conjugated vaccines (PCVs) impact on complex otitis medi

232 Currently, the conjugate vaccine Pfs25-EPA/Alhydrogel is in Phase 1 cli

233 thus show great promise in potentiating the conjugate vaccine platform for application in cancer vac

234 Despite widespread use and high coverage of conjugate vaccines, pneumococcal vaccine serotypes and H

235 in sSA are scarce but essential for typhoid conjugate vaccine policy.

236 mplemented in high-burden countries, typhoid conjugate vaccine presents a promising disease-preventio

237 e critical steps toward reducing the cost of conjugate vaccine production, which will increase access

238 WHO-prequalified ViPS-tetanus toxoid protein conjugate vaccine, providing efficacy estimates for the

239 able, and highly immunogenic meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) was developed to

240 urkina Faso, serogroup A meningococcal (NmA) conjugate vaccine (PsA-TT, MenAfriVac) was introduced th

241 A meningococcal group A conjugate vaccine, PsA-TT (also known as MenAfriVac), wa

242 the introduction of a group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), in 2010, we anal

243 In 2012, a group A meningococcal conjugate vaccine, PsA-TT (MenAfriVac), was introduced i

244 A group A meningococcal conjugate vaccine, PsA-TT, was licensed in 2010 and was

245 ht to bear on the current context of typhoid conjugate vaccine rollouts and extensively drug-resistan

246 Pneumococcal conjugate vaccine serotypes 5, 18C, 19F, and 6A/B were i

247 (75th percentile) for 7-valent pneumococcal conjugate vaccine serotypes and from 58% to 63% for the

248 owever, in the latter years non-pneumococcal conjugate vaccine serotypes were more common.

249 ultiple serotypes, including nonpneumococcal conjugate vaccine serotypes.

250 for the 6 additional 13-valent pneumococcal conjugate vaccine serotypes.

251 NTS vaccines and the introduction of S Typhi conjugate vaccines should be considered for high-inciden

252 Finally, the conjugate vaccine showed immunogenicity and induced prot

253 -response trials comparing free CPS with the conjugate vaccine showed that free CPS is nonimmunogenic

254 GBS CPS III-TT conjugate vaccine significantly delayed acquisition of v

255 nd current candidate capsular polysaccharide conjugate vaccines target only a subset of these.

256 Clinical trials of typhoid conjugate vaccine (TCV) are ongoing in 4 countries.

257 commended the programmatic use of typhoid Vi-conjugate vaccine (TCV) in endemic settings, and Gavi, T

258 8 calling for integration of a novel typhoid conjugate vaccine (TCV) into routine immunization along

259 As typhoid conjugate vaccine (TCV) is rolled out, surveillance shou

260 A typhoid conjugate vaccine (TCV) that was recently prequalified b

261 aims to determine the efficacy of a typhoid conjugate vaccine (TCV) that was recently prequalified b

262 alth Organization (WHO)-prequalified typhoid conjugate vaccine (TCV), Gavi funding for eligible count

263 mination through the introduction of typhoid conjugate vaccine (TCV), we again need to reconsider the

264 lliance (Gavi), for the use of a new typhoid conjugate vaccine (TCV), we should turn our minds to the

265 lth Organization now recommends that typhoid conjugate vaccines (TCV) be used in settings with high t

266 avi's investment decision to support typhoid conjugate vaccines (TCVs) in 2008 and Gavi support becom

267 The introduction of typhoid conjugate vaccines (TCVs) in these settings may relieve

268 and licensure of a new generation of typhoid conjugate vaccines (TCVs) were instrumental in paving th

269 sults of ground-breaking research on typhoid conjugate vaccines (TCVs), the World Health Organization

270 red for use in a glycoconjugate vaccine, but conjugate vaccines tested so far have failed to confer p

271 Recently, a single-dose typhoid conjugate vaccine that allows infants as young as 6 mont

272 ssessing the efficacy of future pneumococcal conjugate vaccines that are under development.

273 e effectiveness of a fentanyl-tetanus toxoid conjugate vaccine to alter fentanyl self-administration

274 accelerate the introduction of a new typhoid conjugate vaccine to reduce the burden of typhoid in cou

275 , since introducing a 13-valent pneumococcal conjugate vaccine to the paediatric immunisation schedul

276 control, including consideration of typhoid conjugate vaccine use as well as nonvaccine control meas

277 sing in prevalence in the wake of widespread conjugate vaccine use, but no wciG-deficient variants ha

278 assessed the efficacy of a Vi-tetanus toxoid conjugate vaccine using an established human infection m

279 ar, the different approaches used to develop conjugate vaccines using peptide/proteins, carbohydrates

280 acy trials can establish the efficacy of new conjugate vaccines using small trials that enroll hundre

281 A typhoid conjugate vaccine (Vi-TCV) was recently prequalified by

282 dies to evaluate co-administering Vi-typhoid conjugate vaccine (Vi-TCV) with routine childhood vaccin

283 A new typhoid conjugate vaccine (Vi-TCV), prequalified by the World He

284 Vi-polysaccharide (Vi-PS), Vi-tetanus-toxoid conjugate vaccine (Vi-TT), live oral Ty21a vaccine, or a

285 Capsular Vi-polysaccharide-protein conjugate vaccines (Vi-conjugate vaccines) are immunogen

286 A single conjugate vaccine was created that elicited high levels

287 y options for opioid use disorders, a heroin conjugate vaccine was developed through comprehensive ev

288 A new group A meningococcal conjugate vaccine was developed to eliminate deadly meni

289 us exposure, vaccination with polysaccharide conjugate vaccine was highly effective, as indicated by

290 A leading nicotine conjugate vaccine was only efficacious for one-third of

291 A new typhoid conjugate vaccine was prequalified by the World Health O

292 duce the next generation of more efficacious conjugate vaccines, we have explored a synthetic design

293 zymes are not suitable for the generation of conjugate vaccines when the polysaccharides contain gluc

294 t the capsule are protective, polysaccharide conjugate vaccines, which are constructed against the mo

295 ntroduction of the meningococcal serogroup A conjugate vaccine within Africa's meningitis belt beginn

296 introduction of a multivalent meningococcal conjugate vaccine within Africa's meningitis belt, will

297 Immunization of children with typhoid conjugate vaccine within Hyderabad city is planned.

298 s in Europe and Africa ensured that the MenA conjugate vaccine would meet all international standards

299 The introduction of a typhoid conjugate vaccine would protect children from typhoid an

300 le-income countries with expanding access to conjugate vaccines, yet there are few data on the incide